Major Japanese Photo Firm Plans Toyama Buy To Enter Drug Market
This article was originally published in PharmAsia News
Fujifilm Holdings plans to acquire Toyama Chemical to make the Japanese pharmaceutical company its first major venture into the drug industry. Fujifilm sees the acquisition worth $9.2 billion in annual sales in 10 years, triple current Fujifilm sales. Fujifilm's president said his company plans other mergers and acquisitions in the medical business to replace the photography business, which has been changed by digital cameras. The Toyama takeover is the latest of a string of 20 takeovers under company president Shigetaka Komori. (Click here for more - a subscription may be required
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.